Results 221 to 230 of about 107,022 (278)

Diastereoselective Synthesis of the HIV Protease Inhibitor Darunavir and Related Derivatives via a Titanium Tetrachloride-Mediated Asymmetric Glycolate Aldol Addition Reaction. [PDF]

J Org Chem
Witte JM, Ayim E, Sams CJ, Service JB, Kant CC, Bambalas L, Wright D, Carter A, Moran K, Rohrig IG, Ferrence GM, Hitchcock SR.   +11 more
europepmc   +1 more source

Pioneer of Medical Mycology: In Memory of Prof. Friedrich Staib, MD, DVM

Mycoses, Volume 69, Issue 7, July 2026.
ABSTRACT At the beginning of Friedrich Staib's academic career in the 1950s, medical mycology was a young discipline in Germany. He studied veterinary and human medicine, earning two doctorates. Initially fascinated by the changes in intestinal flora caused by the newly emerging broad‐spectrum antibacterials, i.e., the selection of fungi.
Barbara Buchberger, Volker Rickerts
wiley   +1 more source

Guidelines for Comparing Circular Dichroism Spectroscopy and Molecular Dynamics Simulations for Biomolecules

ChemPhysChem, Volume 27, Issue 12, 26 June 2026.
A direct comparison is made between circular dichroism (CD) spectroscopy and molecular dynamics (MD) simulations for studying peptide partitioning through biological membranes. The assumptions and limitations of each method is discussed, and case studies are provided for their use.
Cinzia Campus, Marta Roldo, Charles H. Chen, Roja Hadianamrei, Elisabetta Gavini, Christian Jorgensen   +5 more
wiley   +1 more source

Kinetic Fingerprints as Mechanistic and Clinical Roadmaps Across KIT Activation States

ChemMedChem, Volume 21, Issue 11, 15 June 2026.
Kinetic profiling of 172 compounds across KIT conformations—including D816V—reveals kinetic fingerprints that predict efficacy, selectivity, resistance, and inhibitors’ ability to stabilize key regulatory elements. Far from a secondary metric, binding kinetics provide mechanistic insights beyond affinity, offering a powerful framework for rational drug
Ana Corrionero, Niall Prendiville, Tatiana Cazorla, Maria Baena‐Nuevo, Röhm Sandra, Emilio Camafeita, Stefan Knapp, Patricia Alfonso   +7 more
wiley   +1 more source

Antiviral regulator TRIM25 as a prognostic marker of better survival in Merkel cell carcinoma: Association with MCPyV status

International Journal of Cancer, Volume 158, Issue 12, Page 3268-3278, 15 June 2026.
What's new? TRIM25 is known for its role in antiviral immunity and association with poor prognosis in various cancers. This study reveals an association between high TRIM25 expression and Merkel cell polyomavirus positivity in Merkel cell carcinoma.
Klaus W. Fagerstedt, Sami Kilpinen, Johanna Arola, Benjamin Z. Sundqvist, Tom Böhling, Leif C. Andersson, Harri Sihto   +6 more
wiley   +1 more source

HIV Protease Inhibitor [PDF]

, 2020
openaire   +1 more source

Analysis of drug resistance in HIV protease. [PDF]

BMC Bioinformatics, 2018
Pawar SD, Freas C, Weber IT, Harrison RW.   +3 more
europepmc   +1 more source

HIV-1 protease [PDF]

Science-Business eXchange, 2010
openaire   +1 more source

Higher Genotyping Performance of the Applied Biosystems TaqPath Seq HIV-1 Genotyping Kit Against ViroSeq HIV-1 Genotyping Kit in HIV <i>Protease</i>, <i>Reverse Transcriptase</i>, and <i>Integrase</i> Regions. [PDF]

Infect Drug Resist
Choga OT, Okafor O, Lemogang GM, Choga WT, Muzanywa G, Garcia AE, Moyo S, Gaseitsiwe S.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

HIV-Protease Inhibitors

New England Journal of Medicine, 1998
Inhibitors of human immunodeficiency virus (HIV)–encoded protease, combined with nucleoside analogues with antiretroviral activity, cause profound and sustained suppression of viral replication, reduce morbidity, and prolong life in patients with HIV infection.1–3 Recent guidelines recommend that initial treatment of all HIV-infected patients include ...
Charles Flexner, Flexner Charles
exaly   +6 more sources